High-dose methotrexate is commonly used in treatment of a broad spectrum of cancer types, including osteosarcoma, primary CNS lymphoma, acute lymphocytic leukemia, and non-Hodgkin lymphoma. Despite optimal patient management, toxicity due to the use of HDMTX does occur. Oncologic nurses who attend this educational symposium will:
- Become familiar with the principles (indications, precautions) of high-dose methotrexate therapy
- Gain an understanding of the causes of methotrexate toxicity and associated acute kidney injury
- Understand the principles of prevention of methotrexate toxicity (leucovorin rescue, hydration, urinary alkalinization)
- Understand the treatment(s) for methotrexate toxicity and associated acute kidney injury
- Review educational tools and strategies that support the care of patients receiving high-dose methotrexate therapy
This promotional, non-CE educational symposium is sponsored by BTG International Inc.
